The Asia-Pacific Cervical Cancer Diagnostics and Therapeutics market has been estimated at USD 862.14 Million in 2021 and is projected to reach USD 1164.67 Million by 2026, at a CAGR of 6.2% during the forecast period from 2021 to 2026.
Cervical cancer is generally characterized by the abnormal growth of cancerous cells in the tissues of the cervix, and it may manifest itself as a squamous-cell carcinoma or adenocarcinoma. Cervical pre-cancers are diagnosed far more often than invasive cervical cancer. Pap test procedure can find changes in the cervix before cancer develops.
The market for Asia-Pacific Cervical Cancer Diagnostics and Therapeutics is driven by an increasing number of cervical cancer cases, a growing aging population, increasing awareness of cervical cancer screening programs.
But, the market growth may be constrained due to stringent government regulations and high costs of technology of screening tests.
This research report on the Asia Pacific Cervical Cancer Diagnostics and Therapeutics Market is segmented and sub-segmented into the following categories:
By Diagnostics Test:
By Methods:
By Therapies:
By End-users:
By Country:
On the basis of diagnostics test, the Pap smear test segment dominated the market by Diagnostic test, holding a 45% share in the global market for cervical cancer diagnostic tests. The high growth rate of this segment can be attributed to the high efficiency of the test, low cost of the test in comparison with other tests available in the market, and rising awareness regarding a cancer diagnosis.
Asia Pacific market is growing at a very high rate, due to rising consumer size, favorable government support for enhanced healthcare infrastructure, and rising awareness for healthcare among the population in developing nations of the region.
The Top companies leading in the APAC Cervical Cancer Diagnostics and Therapeutics market profiled in this report are Abbott Diagnostics, Alere, Beckman Coulter, Clinical Genomics, Companion Dx, EDP Biotech, Epigenomics AG, Exact Sciences, Fujirebio, Genomic Tree, Metabiomics, Oncocyte (Biotime), Quest Diagnostics, Randox Laboratories, Siemens Healthcare and Volition Rx.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By diagnostics test
5.1.1 Pap smear test
5.1.2 HPV testing
5.1.3 Colposcopy
5.1.4 Cervical cancer biopsy
5.2 By methods
5.2.1 Molecular method
5.2.2 Cytopathological method
5.2.3 Physical method
5.3 By therapies
5.3.1 Surgery
5.3.2 Radiation therapy
5.3.3 Chemotherapy
5.3.4 Other therapies
5.4 By end-users
5.4.1 Hospitals
5.4.2 Laboratories
5.4.3 Independent physicians
5.4.4 Clinics
5.4.5 Other end-users
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
8. Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 Abbott Diagnostics
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 Alere
9.3 Beckman Coulter
9.4 Clinical Genomics
9.5 Companion Dx
9.6 EDP Biotech
9.7 Epigenomics AG
9.8 Exact Sciences
9.9 Fujirebio
9.10 Genomic Tree
9.11 Metabiomics
9.12 Siemens Healthcare
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
